Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Tetzlaff

Showing results (121-130 of 224) with videos related to

Pageof 23
Sort By:
Nature Communications|June 30, 2021
Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1Yue Lu, Alphonsus H C Ng, Frances E Chow, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesionsEugen C Minca, Rami N Al-Rohil, Min Wang, et al.
Journal of Cutaneous Pathology|April 11, 2018
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous patternCelestine Trinidad, Kelly C Nelson, Isabella C Glitza Oliva, et al.
Journal of Cutaneous Pathology|July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumorKrishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Oncoimmunology|June 23, 2017
Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicatorsIvan V Litvinov, Michael T Tetzlaff, Philippe Thibault, et al.
Oncoimmunology|September 18, 2018
Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patientsPhilippe Lefrançois, Pingxing Xie, Linghua Wang, et al.
Journal of Cutaneous Pathology|November 19, 2016
Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJonathan L Curry, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?Katrina Collins, Jun Gu, Phyu P Aung, et al.
Biomed Research International|December 26, 2013
Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomasVicki H Chu, Michael T Tetzlaff, Carlos A Torres-Cabala, et al.
Pageof 23

Showing results (121-130 of 224) with videos related to

Sort By:
Pageof 23
Nature Communications|June 30, 2021
Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1Yue Lu, Alphonsus H C Ng, Frances E Chow, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesionsEugen C Minca, Rami N Al-Rohil, Min Wang, et al.
Journal of Cutaneous Pathology|April 11, 2018
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous patternCelestine Trinidad, Kelly C Nelson, Isabella C Glitza Oliva, et al.
Journal of Cutaneous Pathology|July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumorKrishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Oncoimmunology|June 23, 2017
Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicatorsIvan V Litvinov, Michael T Tetzlaff, Philippe Thibault, et al.
Oncoimmunology|September 18, 2018
Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patientsPhilippe Lefrançois, Pingxing Xie, Linghua Wang, et al.
Journal of Cutaneous Pathology|November 19, 2016
Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJonathan L Curry, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?Katrina Collins, Jun Gu, Phyu P Aung, et al.
Biomed Research International|December 26, 2013
Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomasVicki H Chu, Michael T Tetzlaff, Carlos A Torres-Cabala, et al.
Pageof 23